Fulcrum Therapeutics financials
$3.70−0.54%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $80.0M | $0.00 | $871.0K | $759.0K |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $80.0M | $0.00 | $871.0K | $759.0K |
| Gross margin | — | — | — | — | — | — | — | — | 100.0% | — | 100.0% | 100.0% |
| Operating income | -$29.3M | -$22.2M | -$22.7M | -$21.9M | -$19.8M | -$20.4M | -$19.4M | -$25.1M | $52.5M | -$29.8M | -$28.0M | -$27.4M |
| Net income | -$26.2M | -$18.9M | -$20.3M | -$19.6M | -$17.3M | -$17.7M | -$16.6M | -$21.7M | $55.4M | -$26.9M | -$24.8M | -$24.0M |
| Net margin | — | — | — | — | — | — | — | — | 69.3% | — | −2842.3% | −3164.3% |
| Diluted EPS | $-0.34 | $-0.25 | $-0.31 | $-0.31 | $-0.28 | $-0.28 | $-0.28 | $-0.35 | $0.87 | $-0.43 | $-0.40 | $-0.39 |
| EBITDA | -$19.7M | -$21.8M | -$22.3M | -$21.5M | -$19.5M | -$20.1M | -$19.1M | -$22.7M | $52.9M | -$29.4M | -$27.5M | -$26.9M |
| Operating cash flow | -$16.0M | -$18.8M | -$16.8M | -$14.2M | -$13.8M | -$15.3M | -$16.8M | -$19.1M | $58.9M | -$25.3M | -$23.2M | -$22.9M |
| Free cash flow | -$16.1M | -$18.8M | -$17.0M | -$14.3M | -$13.9M | -$15.3M | -$17.0M | -$19.1M | $58.9M | -$25.3M | -$23.2M | -$23.0M |
| Diluted shares | 76.3M | 76.2M | 65.8M | 62.6M | 62.5M | 62.5M | 60.0M | 62.4M | 63.6M | 62.0M | 61.9M | 61.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $48.5M | $50.3M | $197.5M | $47.1M | $42.6M | $42.2M |
| Short-term investments | $270.4M | $283.1M | $154.8M | $153.6M | $171.5M | $184.4M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $324.0M | $346.8M | $366.3M | $214.9M | $228.8M | $242.6M |
| Total liabilities | $13.3M | $13.5M | $17.3M | $16.5M | $14.5M | $14.2M |
| Shareholders' equity | $310.7M | $333.3M | $349.0M | $198.4M | $214.4M | $228.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology